Table 4 Univariate and multivariate analysis of predictive factors for CSS in discovery cohort (n = 165).

From: FAN score comprising fibrosis-4 index, albumin–bilirubin score and neutrophil–lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumab

 

Univariate

Multivariate

HR

95% CI

p

HR

95%CI

p

Lower

Higher

Lower

Higher

Age

 < 73 vs. ≥ 73

1.26

0.86

1.84

0.240

1.19

0.79

1.79

0.409

Sex

Male vs. female

1.47

0.98

2.19

0.061

1.28

0.85

1.94

0.238

Primary site

Upper urinary tract involvement vs. others

1.10

0.74

1.63

0.629

    

Surgical removal of primary site

no vs. yes

0.72

0.49

1.06

0.092

    

Previous chemotherapy regimen

Cisplatin vs. non-cisplatin

1.05

0.71

1.55

0.805

    

Time from last chemotherapy (days)

 ≥ 90 vs. < 90

1.57

1.06

2.32

0.025

1.29

0.85

1.96

0.227

Hb (g/dl)

 ≥ 10.0 vs. < 10.0

1.73

1.18

2.53

 < 0.001

1.26

0.83

1.91

0.287

ECOG performance status

0 vs. 1

2.28

1.44

3.62

 < 0.001

2.32

1.44

3.72

0.001

0 vs. ≥ 2

3.33

1.89

5.85

 < 0.001

3.05

1.70

5.47

< 0.001

Metastatic sites

Lymphnode vs. other organs

1.17

0.74

1.85

0.509

1.04

0.65

1.66

0.884

Lymphnode vs. liver metastasis

1.95

1.13

3.38

0.017

1.48

0.84

2.62

0.180

eGFR (ml/min/1.73 m2)

 ≥ 60 vs. 30.0 ≤ , < 60.0

0.78

0.48

1.29

0.665

    

 ≥ 60 vs. < 30

1.41

0.75

2.62

0.283

    

FAN score

Low risk group vs. high risk group

1.61

1.32

1.98

 < 0.001

1.48

1.19

1.83

 < 0.001

  1. Hb: hemoglobin, ECOG: Eastern Cooperative Oncology Group, eGFR: estimated glomerular filtration rate, FAN: Fib-4 index, ALBI score and NLR, HR: hazard ratio, CI: confidence interval.
Back to article page